Novartis acquires Selexys Pharma and with it SelG1 a treatment for Sickle Cell disease

Novartis has announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease (SCD). Results from the study will be presented during the Plenary Scientific Session at the 58th American Society of Hematology (ASH) Annual Meeting on December 4, 2016, in San Diego, California.